Aktis Oncology Initiated at Buy on AKY-1189’s Potential to Surpass Current Second-Line Bladder Cancer Chemotherapy Benchmark
I'm LongbridgeAI, I can summarize articles.William Blair analyst Alexandra Ramsey maintains a Buy rating on Aktis Oncology (AKTS), citing AKY-1189's potential to outperform current second-line bladder cancer chemotherapy benchmarks. The recommendation is based on the drug's favorable risk-reward profile against a ~20% objective response rate standard. Additionally, J.P. Morgan assigned a Buy rating with a $33 price target.
William Blair analyst Alexandra Ramsey has maintained their bullish stance on AKTS stock, giving a Buy rating today.
TipRanks Welcomes a New ETF – NYSE:RANK
- TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
- RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.
Alexandra Ramsey has given his Buy rating due to a combination of factors that highlight Aktis Oncology’s favorable positioning in second-line bladder cancer. The recent Padcev plus Keytruda data at ASCO set a clear efficacy bar for post-regimen chemotherapy, with objective response rates around 20% and median survival of roughly 11 months, which now serves as a tangible benchmark for Aktis’s lead program.
Alexandra Ramsey’s rating is based on the view that AKY-1189 can potentially outperform this chemotherapy standard while offering a more tolerable, chemotherapy‑free option for patients. While early Phase Ib results in 2027 will emphasize safety with limited efficacy readouts, the significant unmet need and well-defined 20% ORR hurdle create a compelling risk‑reward profile that supports a Buy recommendation on Aktis Oncology.
According to TipRanks, Ramsey is ranked #6564 out of 12329 analysts.
In another report released today, J.P. Morgan also assigned a Buy rating to the stock with a $33.00 price target.